TOMSK, RUSSIA / RankWire.AI / – Russian scientists have evaluated a bioactive coating aimed at enhancing the interaction between titanium orthopedic implants and bone tissue. This material incorporates calcium phosphate sourced from hydroxyapatite and includes nitrogen compounds linked to nitric oxide production. Laboratory experiments demonstrated a markedly increased survival rate of human mesenchymal stem cells on coated surfaces compared to uncoated titanium. The researchers analyzed the coating’s structure, chemical makeup, mechanical attributes, and biological effects. Their peer-reviewed results were published in Applied Surface Science in 2026.
At Tomsk Polytechnic University, scientists developed the experimental coatings through reactive magnetron sputtering of a hydroxyapatite target within a vacuum chamber. They adjusted the nitrogen to argon ratio during deposition to observe how each mixture influenced the surface properties. Five different conditions were tested, from pure nitrogen to pure argon. The team measured parameters such as coating thickness, surface morphology, hardness, wettability, and chemical composition. Additionally, they performed laboratory assessments to determine how living human cells responded to the modified titanium surfaces.
Results indicated that the argon content influenced several physical characteristics of the coatings. Surfaces created in pure argon were found to be denser and harder than those produced with pure nitrogen. An increase in coating thickness was also observed as the proportion of argon grew. Chemical analysis revealed nitrogen-carbon and nitrogen-oxygen bonds on the modified surfaces. Subsequently, researchers compared the response of human mesenchymal stem cells grown on coated titanium with cells cultured on uncoated titanium. The biological tests focused on cell viability and markers associated with bone-cell differentiation.
Enhanced cell viability observed on coated surfaces
According to the study, cell experiments demonstrated significantly improved survival rates on coated surfaces relative to uncoated titanium. After seven days, coatings with higher nitrogen levels also suppressed activity in certain genes linked to early bone-cell differentiation. Despite these changes, the cells maintained their ability to form bone tissue. These evaluations were conducted under controlled laboratory conditions using human mesenchymal stem cells, and the study did not involve testing in human patients or assessing clinical implant performance.
The biomedical assessment was carried out by researchers from Immanuel Kant Baltic Federal University and Siberian State Medical University. The project also included contributions from Saint Petersburg State University. Funding was provided through Russia’s national science program. The focus was on identifying gas mixtures capable of producing coatings with advantageous physical, chemical, and biological properties. Hydroxyapatite, due to its calcium phosphate composition resembling the mineral component of human bone, has long been used in implant coatings.
Current findings are confined to laboratory experiments
The research team outlined plans for additional testing beyond the initial seven-day cell evaluations. They intend to analyze stem cell responses over periods from 10 to 28 days and investigate the rate of coating dissolution. Future studies will also measure nitric oxide release into surrounding tissues in living organisms. These subsequent investigations are outside the scope of the current publication, which centers on coated titanium substrates, their properties, and in vitro cellular responses, rather than clinical outcomes in orthopedic patients.
The study offers detailed laboratory data on how varying ratios of nitrogen and argon influence calcium phosphate coatings on titanium. Differences in coating thickness, density, hardness, chemical bonds, and cellular responses across the tested gas mixtures were documented. The results confirmed that coated samples supported higher stem-cell survival than uncoated titanium under experimental conditions. Nevertheless, the research remains at the preclinical stage, and the published experiments do not establish safety or efficacy in human patients. Additional biological testing will be necessary to evaluate properties not covered in the current study.